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rom B-Type Natriuretic
eptide to Green Mambas
he Process of Discovery*
ary S. Francis, MD, FACC
leveland, Ohio
he study by Lisy et al. (1) in this issue of the Journal
eports on the design, synthesis, and properties of a new
himeric natriuretic peptide (1). The work represents an
ngoing interest by the Mayo Clinic Burnett Laboratory in
he development of therapy that will increase natriuresis and
iuresis without attendant hypotension. B-type natriuretic
eptide (BNP) is a counter-regulatory endogenous neuro-
ormone that is synthesized by the heart and released in
esponse to increased myocardial wall stress in conditions
uch as heart failure. However, the amount of BNP released,
hough often substantial, can be of insufficient quantity to
ffset the excessive vasoconstrictor and sodium-water reten-
ive state characteristic of advanced heart failure. This is, in
art, because only a small amount of BNP is actually stored
n the heart (relative to atrial natriuretic peptide), and its
elease is in large measure regulated by myocardial BNP
ynthesis rather than by storage capacity. To synthesize new
NP is presumably a more time-consuming process than
elease of BNP from storage vesicles.
See page 60
With this problem in mind, synthetic exogenous BNP
nesiritide) was developed by Scios (Mountain View, Cali-
ornia) using a recombinant deoxyribonucleic acid technique
o produce essentially pure BNP. Although initial sales of
esiritide were robust, clinicians eventually recognized that
esiritide often had only a modest effect on natriuresis,
iuresis, and renal function in patients with acute decom-
ensated heart failure (2). Some problems with nesiritide
rose (3), but have now been more or less laid to rest by the
afety record of the FUSION-2 (Follow-Up Serial Infusion
f Nesiritide in Advanced Heart Failure) study. The large
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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cios and Biosite.SCEND-HF (Acute Study of Clinical Effectiveness of
esiritide in Decompensated Heart Failure) mortality trial
as now been launched. Some loss of confidence in nesirit-
de has occurred despite very careful and tightly controlled
tudies by the Burnett Laboratory. The Mayo Clinic inves-
igations had consisted primarily of inducement of experi-
ental heart failure by rapid pacing in animals and subse-
uent demonstration of significant diuretic and natriuretic
ffects of nesiritide in this model. One might ask, how did
his disparity occur?
Looking back on our experience, the strategy of giving a
xed bolus of nesiritide followed by an infusion was prob-
bly not a prudent strategy. Very often patients receiving
esiritide had been aggressively pre-treated with intrave-
ous loop diuretics. They may have been in a state of intense
asoconstriction due to activation of the neurohumoral
ystems (4), might have had marginal blood pressure after
ntravenous loop diuretics, and in some cases were likely
ade more hypotensive by a bolus and infusion of nesiritide.
erhaps a more rational strategy would have been to
emporarily stop the diuretics, forego the bolus of nesiritide,
nd give only one-half the recommended maintenance
nfusion dose slowly over several days so as to not further
ower blood pressure to signal the kidney to retain salt and
ater. Loop diuretics could be added back as needed.
iving a smaller maintenance dose of nesiritide (0.005
g/kg/min) over a longer period of time without additional
arge boluses of intravenous loop diuretics might lead to
etter outcomes with nesiritide use (5), but we simply do
ot have the data. Renal blood flow probably has to be well
aintained for any natriuretic peptide to work properly.
That being said, the Burnett group has now developed an
ntirely new strategy. They have designed, synthesized, and
tudied a novel chimeric natriuretic peptide. It is a hybrid
olecule that includes the C-terminus tail of exogenous
endraspis natriuretic peptide (DNP) and the 22-amino
cid endogenous peptide C-type natriuretic peptide (CNP)
o create CD-NP. The new chimeric molecule includes the
hole CNP molecule, a vasodilator peptide with essentially
o renal actions, and the natriuretic and diuretic properties
f the C-terminus of DNP. The ring structure of DNP is
ot included for good reasons, as it causes marked hypo-
ension, and essentially serves as a lethal defense mechanism
or the green mamba snake (Denarbaspis angusticeps). The
ong C-terminus of the DNP peptide probably allows for
ess degradation by endopeptidases per unit time, thus
rolonging the action of CD-NP. When injected into
ormal anesthetized dogs, CD-NP increased urinary so-
ium excretion, urine flow, and glomerular filtration rate
espite a slight decrease in mean arterial pressure during
nfusion of the high dose. Renal blood flow was not
easured. CD-NP also suppressed cell proliferation in
ultured human fibroblasts using cardiotropin-1 stimula-
ion, an antiremodeling effect previously observed with atrial
atriuretic peptide (6).
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Editorial Comment July 1, 2008:69–70The authors should be congratulated for engineering a
ovel chimeric protein that has real therapeutic possibilities.
he protein chemistry was probably not easy. Further
tudies will, of course, be necessary, and should include
easures of renal blood flow and renal function in animals
ith heart failure, where the proclivity to retain salt and
ater may possibly offset the natriuretic and diuretic re-
ponses to CD-NP. Understanding how to dose the new
olecule will be critical, as in retrospect, an imprudent
ront-loaded dosing schedule for nesiritide may have ham-
ered our understanding of how to best use this exogenous
atriuretic peptide.
Beyond the elegant biochemistry involved in the devel-
pment of CD-NP, the authors are to be also congratulated
or their pure reasoning powers in the design of this novel
himeric molecule. Linking molecular structure to function
equires imagination and creativity, two of the most impor-
ant hallmarks of good science. Clinicians are at times too
uick to latch on to a “new drug” without thinking or caring
bout what part of the molecule is responsible for a specific
ctivity. Perhaps just seeing that long C-terminus tail of
NP was enough to awaken the Mayo Clinic investigators
o interesting new possibilities about how to create a better
atriuretic peptide molecule. This work represents a classic
xample of how to take advantage of a prepared mind. To
he noncognoscente, the DNP amino-acid sequence prob-
bly meant little beyond just another peptide sequence in
nake venom from a different species. To the Burnett
aboratory, the C-terminus perhaps immediately suggested a
ost interesting hypothesis to test. They then proceeded to
evelop a chimeric molecule that incorporated the best
K
Deatures of CNP and DNP. It represents an example
hereby investigators can “move a field” through the
owers of careful observation and reason. We look forward
o additional studies with this interesting new chimeric
olecule.
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